Stocks News

LAST PRICE
128.1300
TODAY'S CHANGE (%)
Trending Up2.3600 (1.8764%)

Bid / Lots
124.8300/ 1
Ask / Lots
131.5000/ 1
Open / Previous Close
124.5200 / 125.7700
Day Range
Low 122.1300
High 129.3100
52 Week Range
Low 86.5450
High 161.0000
Volume
282,035
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Yesterday
- Ascendis, Novo Nordisk to Develop, Commercialize Products in Metabolic, Cardiovascular Diseases, from 11:01AM ET on Monday Nov 04, 2024 by MT Newswires
  11:01AM ET on Monday Nov 04, 2024 by MT Newswires
  Companies Mentioned: NVO, ASND
  11:01 AM EST, 11/04/2024 (MT Newswires) -- Ascendis Pharma (ASND) said Monday it granted Novo Nordisk (NVO) an exclusive global license to develop and commercialize TransCon technology-based products in metabolic diseases and a product-by-product ex...
- DJ Ascendis Pharma Price Target Maintained With a $170.00/Share by Cantor Fitzgerald, from 8:53AM ET on Monday Nov 04, 2024 by Dow Jones
  8:53AM ET on Monday Nov 04, 2024 by Dow Jones
  Companies Mentioned: ASND
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/ASND/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 04, 2024 08:53 ET (13:53 GMT)
- Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases, from 7:00AM ET on Monday Nov 04, 2024 by Dow Jones
  7:00AM ET on Monday Nov 04, 2024 by Dow Jones
  Companies Mentioned: ASND
  
  - Collaboration leverages Ascendis' proprietary TransCon(TM) technologies and Novo Nordisk's expertise in cardiometabolic diseases
  
  - Once-monthly GLP-1 receptor agonist will be the collaboration's lead product candidate
Oct 29, 2024
- European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading, from 11:12AM ET on Tuesday Oct 29, 2024 by MT Newswires
  11:12AM ET on Tuesday Oct 29, 2024 by MT Newswires
  Companies Mentioned: HSBC, NOK, PSO, VOD, OPRA, DAVA, GNFT, AKTX, BP, CRTO, TCBP, MTLS, DBVT, ASND, SAN, BDRX
  11:12 AM EDT, 10/29/2024 (MT Newswires) -- European equities traded in the US as American depositary receipts were moving lower late Tuesday morning, declining 0.22% to 1,388.98 on the S&P Europe Select ADR Index. From continental Europe, the gainer...
Oct 28, 2024
- European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading, from 11:16AM ET on Monday Oct 28, 2024 by MT Newswires
  11:16AM ET on Monday Oct 28, 2024 by MT Newswires
  Companies Mentioned: LYG, PHG, VEON, EQNR, TRIB, NCNA, BP, SHEL, MTLS, DBVT, ASND, CUK, CLLS, ADAP, BDRX, EDAP
  11:16 AM EDT, 10/28/2024 (MT Newswires) -- European equities traded in the US as American depositary receipts were moving higher late Monday morning, rising 0.4% to 1,391.20 on the S&P Europe Select ADR Index. From continental Europe, the gainers we...

Today
- Tempus AI Shares Fall After Reporting Q3 Loss, Deal to Acquire Ambry Genetics for $600 Million, from 4 hours ago by MT Newswires
  4 hours ago by MT Newswires
  Companies Mentioned: TEM
- Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma, from 8 hours ago by Dow Jones
  8 hours ago by Dow Jones
  Companies Mentioned: LEGN
- Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia, from 10 hours ago by Dow Jones
  10 hours ago by Dow Jones
  Companies Mentioned: ITCI
Yesterday
- DJ Tempus AI Agrees to Acquire Ambry Genetics, from 22 hours ago by Dow Jones
  22 hours ago by Dow Jones
  Companies Mentioned: TEM
- -- Earnings Flash (TEM) TEMPUS AI Reports Q3 Revenue $180.9M, from 4:06PM ET on Monday Nov 04, 2024 by MT Newswires
  4:06PM ET on Monday Nov 04, 2024 by MT Newswires
  Companies Mentioned: TEM
- -- Earnings Flash (TEM) TEMPUS AI Reports Q3 Loss $-0.25, from 4:06PM ET on Monday Nov 04, 2024 by MT Newswires
  4:06PM ET on Monday Nov 04, 2024 by MT Newswires
  Companies Mentioned: TEM
- Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics, from 4:01PM ET on Monday Nov 04, 2024 by Dow Jones
  4:01PM ET on Monday Nov 04, 2024 by Dow Jones
  Companies Mentioned: TEM
- *DJ Tempus Reports Third Quarter 2024 Results And Agreement To Acquire Ambry Genetics >TEM, from 4:01PM ET on Monday Nov 04, 2024 by Dow Jones
  4:01PM ET on Monday Nov 04, 2024 by Dow Jones
  Companies Mentioned: TEM
- DJ Intra-Cellular Therapies Is Maintained at Overweight by JP Morgan, from 9:34AM ET on Monday Nov 04, 2024 by Dow Jones
  9:34AM ET on Monday Nov 04, 2024 by Dow Jones
  Companies Mentioned: ITCI
- Legend Biotech Appoints Alan Bash as President of CARVYKTI(R), from 7:30AM ET on Monday Nov 04, 2024 by Dow Jones
  7:30AM ET on Monday Nov 04, 2024 by Dow Jones
  Companies Mentioned: LEGN

Ascendis Pharma A/S
NASDAQ:ASNDUnited States

Search Criteria

Yesterday

Ascendis, Novo Nordisk to Develop, Commercialize Products in Metabolic, Cardiovascular Diseases, from 11:01AM ET on Monday Nov 04, 2024 by MT Newswires

DJ Ascendis Pharma Price Target Maintained With a $170.00/Share by Cantor Fitzgerald, from 8:53AM ET on Monday Nov 04, 2024 by Dow Jones

Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases, from 7:00AM ET on Monday Nov 04, 2024 by Dow Jones

Oct 29, 2024

European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading, from 11:12AM ET on Tuesday Oct 29, 2024 by MT Newswires

Oct 28, 2024

European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading, from 11:16AM ET on Monday Oct 28, 2024 by MT Newswires

Peers Headlines

Today

Tempus AI Shares Fall After Reporting Q3 Loss, Deal to Acquire Ambry Genetics for $600 Million, from 4 hours ago by MT Newswires

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma, from 8 hours ago by Dow Jones

Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia, from 10 hours ago by Dow Jones

Yesterday

DJ Tempus AI Agrees to Acquire Ambry Genetics, from 22 hours ago by Dow Jones

-- Earnings Flash (TEM) TEMPUS AI Reports Q3 Revenue $180.9M, from 4:06PM ET on Monday Nov 04, 2024 by MT Newswires

-- Earnings Flash (TEM) TEMPUS AI Reports Q3 Loss $-0.25, from 4:06PM ET on Monday Nov 04, 2024 by MT Newswires

Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics, from 4:01PM ET on Monday Nov 04, 2024 by Dow Jones

*DJ Tempus Reports Third Quarter 2024 Results And Agreement To Acquire Ambry Genetics >TEM, from 4:01PM ET on Monday Nov 04, 2024 by Dow Jones

DJ Intra-Cellular Therapies Is Maintained at Overweight by JP Morgan, from 9:34AM ET on Monday Nov 04, 2024 by Dow Jones

Legend Biotech Appoints Alan Bash as President of CARVYKTI(R), from 7:30AM ET on Monday Nov 04, 2024 by Dow Jones